Lakefront Biotherapeutics (LKFT) Non-Current Deffered Revenue (2016 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Non-Current Deffered Revenue for 10 consecutive years, with $779.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue fell 20.93% year-over-year to $779.0 million; the TTM figure through Sep 2025 stood at $779.0 million (down 20.93% YoY), while the FY2024 annual figure was $896.4 million, down 22.22% from the prior year.
• Non-Current Deffered Revenue slipped to $779.0 million in Q3 2025 per LKFT's latest filing, from $819.3 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $2.6 billion in Q2 2021 and bottomed at $779.0 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $1.4 billion across 5 years, with a median of $1.2 billion in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue declined 3.0% — and 2024, when it tumbled 31.35%.
• Lakefront Biotherapeutics' Non-Current Deffered Revenue stood at $2.2 billion in 2021, then declined by 25.55% to $1.7 billion in 2022, then sank by 30.42% to $1.2 billion in 2023, then slipped by 22.22% to $896.4 million in 2024, then slipped by 13.1% to $779.0 million in 2025.
• Business Quant data shows LKFT's Non-Current Deffered Revenue at $779.0 million in Q3 2025, $819.3 million in Q2 2025, and $821.9 million in Q1 2025.